Phaseline

Companies › Ensoma

Ensoma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EN-374
Gene therapy delivering functional CYBB gene to restore NADPH oxidase activity in neutroph
CYBBPhase 1X-Linked Chronic Granulomatous DiseaseDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06876363EN-374Phase 1X-Linked Chronic Granulomatous DiseaseHematologyDec 2027

Targets

CYBB (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.